Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Aug 9, 2016View HTMLDownload DOCDownload PDFDownload XLS
8-K/AAmendment to a previously filed 8-KAug 8, 2016View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionAug 8, 2016View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersAug 8, 2016View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventAug 4, 2016View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesAug 3, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesAug 3, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesAug 3, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 28, 2016View HTMLDownload DOCDownload PDF
UPLOADCorrespondence from the SEC to the FilerJul 26, 2016Download DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 26, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 20, 2016View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJul 19, 2016View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Jul 19, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 19, 2016View HTMLDownload DOCDownload PDF
3Initial filing by director officer or owner of more than ten percent.Jul 19, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 19, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 18, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJul 11, 2016View HTMLDownload DOCDownload PDF
CORRESPCorrespondence from the Filer to the SECJul 8, 2016View HTMLDownload DOCDownload PDFDownload XLS
UPLOADCorrespondence from the SEC to the FilerJun 24, 2016Download DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 21, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 20, 2016View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJun 10, 2016View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 8, 2016View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-136

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information